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Abstract: The phosphoinositide 3-kinases (PI3Ks) constitute an important family of lipid kinase enzymes that control a range of cellular 
processes through their regulation of a network of signal transduction pathways, and have emerged as important therapeutic targets in the 
context of cancer, inflammation and cardiovascular diseases. Since the mid-late 1990s, considerable progress has been made in the 
discovery and development of small molecule ATP-competitive PI3K inhibitors, a number of which have entered early phase human 
trials over recent years from which key clinical results are now being disclosed. This review summarizes progress made to date, primarily 
on the discovery and characterization of class I and dual class I/IV subtype inhibitors, together with advances that have been made in 
translational and clinical research, notably in cancer. 
Keywords: PI3K, inhibitor, p110, p110, p110, p110, mTOR, cancer, inflammation, cardiovascular. 
1. INTRODUCTION 
The PI3K superfamily has, over the past 15 years, become one 
of the most extensively studied classes of therapeutic targets in 
small molecule drug discovery, particularly in oncology [1-4]. Four 
distinct PI3K subfamilies exist – commonly referred to as class I, II, 
III and IV – based upon their substrate specificities, primary 
structures, modes of regulation and domain content. Of these, it is 
the class I isoforms, p110, p110, p110 and p110, together with 
the class IV PI3K-related kinase (PIKK), mTOR [5,6], which have 
been the most intensively examined targets in the small molecule 
therapeutic arena, and which form the principal subject of this 
present discussion. 
2. CLASS I PI3K ISOFORMS AND mTOR IN CHRONIC 
DISEASE: POTENTIAL FOR SMALL MOLECULE 
INHIBITORS 
The majority of small molecule discovery research in the PI3K 
field has, to date, centred on class I inhibitors for the treatment of 
cancer. The key mechanistic rationale for this stems from the class I 
PI3K/AKT pathway being dysregulated in a tissue-diverse range of 
tumours [1-4, 7,8]. The phosphatase PTEN, the negative regulator 
of PI3K, is one of the most commonly mutated proteins in human 
malignancy [9]. Furthermore, the gene encoding for the p110 
subunit,  PIK3CA, is amplified, overexpressed and frequently 
mutated in many cancers [10]; critically, these mutations have been 
shown to reduce cellular dependence on growth factors, to attenuate 
apoptosis, and to facilitate tumour invasiveness. Additionally, a 
greater understanding of the specific roles of the p110 and p110 
isoforms in tumourigenesis has recently been established: it has 
been shown that p110 is critical for the growth of tumours driven 
by  PIK3CA mutations as well as oncogenic receptor tyrosine 
kinases and RAS, whilst p110 is the principal isoform involved in 
mediating PTEN-deficient tumourigenesis [11-13]. In addition, 
p110 has also emerged as a key therapeutic target for 
haematological malignancies [14,15], notably acute myeloid 
leukaemia (AML), and there is also some evidence that this isoform  
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is upregulated in melanoma and breast cancer, and is overexpressed 
in neuroblastoma [4]. Furthermore, there is potential for all the 
class I PI3Ks to be activated in cancer cells through mutation of the 
p85 regulatory subunits. Consequently, inhibition of class IA PI3Ks 
– p110, p110 and p110 – represents an important strategy for 
the development of novel cancer therapeutics, and, moving forward, 
is anticipated to have a significant impact on the discovery and 
development of new personalized medicines in the oncology 
setting. 
In addition to PTEN-null tumours, p110 has been pursued as a 
target for antithrombotic therapy [16], and there is also growing 
evidence that p110 inhibitors could have significant therapeutic 
potential in autoimmune diseases [17-19]. Furthermore, p110 has 
been reported to play an important role in mast cell, eosinophil and 
neutrophil function [20]. Interestingly, the p110 isoform was the 
first of the PI3K enzyme family for which a liganded crystal 
structure was resolved [21], and it has since been the subject of a 
number of small molecule R&D activities [4]. However, at the time 
of writing, there are no examples of p110-specific inhibitors to 
have entered clinical development. By contrast, the p110 subtype, 
which has also been shown to play a central function in the 
recruitment and activation of a range of immune and inflammatory 
cells [22-24], has become a hotly pursued target in small molecule 
drug discovery circles. Co-crystal structures of this isoform were 
recently resolved [25], and there are several p110-targeted 
inhibitors that are currently in preclinical development – with two 
having now entered early phase clinical studies – for the treatment 
of haematological cancer and immune-inflammatory disorders 
[4,26]. 
Finally, there has been significant recent progress made in the 
discovery of new small molecules that target the PIKK sub-family 
member, mTOR. This protein was originally discovered in the 
1990s, when the mechanism of action of rapamycin, a macrolide-
based natural product with immunosuppressant activity, was 
elucidated [27]. Rapamycin and derivatives thereof bind with high 
afﬁnity to the immunophilin FK506-binding protein-12 (FKBP12), 
forming a complex that selectively inhibits mTORC1 downstream 
signalling to elements involved in growth control, and they have 
since been evaluated as agents for the treatment of solid tumours 
[4]. In addition, recent progress been made in targeting the ATP-
binding site of mTOR with small molecule inhibitors that exhibit 
anti-tumour activity. Of particular significance to this present 
review, however, is the discovery and development of a number of 
small molecules that dually inhibit class I PI3Ks – particularly 
p110 – together with mTOR for the treatment of cancer, and these Progress in the Preclinical Discovery  Current Medicinal Chemistry,  2011 Vol. 18, No. 18      2687 
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Wortmannin: IC50 of 4, 1nM, 4 and 9nM against p110, ,  and  
respectively 
[29] 
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N
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GDC-0941: IC50 of 3, 33, 3 and 75nM against p110, ,  and  
respectively 
[33,34] 
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XL147: IC50 p110, , ,  = 39, 383, 36, and 23nM respectively  [35] 
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GSK1059615: IC50 p110, , ,  and mTOR = 0.4, 0.6, 2, 5 and 
12nM respectively 
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PX-866: IC50 p110,  and  = 6nM, 3nM and 9nM respectively; 
p110 > 300μM  [29] 
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CAL-101: IC50 p110, ,  and  = >100μM, 1.82μM, 70nM and 
1.24μM respectively  [38]  
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SF1126: IC50 p110, ,  and  = 356, 736, 3225, 1774nM 
respectively; 
IC50 mTOR, DNA-PK = 1060 and 357nM respectively 
[39] 
10  N
N
NMe
N
CN
O
 
NVP-BEZ235: IC50 p110, , ,  and mTOR = 4, 75, 7, 5, 21nM 
respectively 
[40] 
11 
N N
NH HN O2S
OMe
OMe HN
Me
MeO
O
 
XL765: IC50 p110, , ,  and mTOR= 39, 113, 43, 9 and 157nM 
respectively 
[41] 
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GSK2126458: Ki p110, , ,  and mTORC1 = 19, 130, 24, 60 
and 180pM respectively  [36] 
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TG100115: IC50 p110, ,  and  = 1.3μM, 1.2μM, 235nM and 
83nM respectively 
[29] 
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N
N
Me NH
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TGX 221: IC50 p110 = 5nM; p110 = 5μM, p110 = 100nM, 
p110 > 10μM  
[42] 
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Heterodimer of LY294002 and geldanamycin exhibits activity 
against PI3K and Hsp90  [43] 
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17-Hydroxywortmannin: IC50 p110 = 2.7nM  [44] 
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PWT-458, a pegylated derivative of 17-hydroxywortmannin with 
improved tolerability profile compared with 16  [45] 
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PI-103: IC50, p110 = 3.6nM, p110 = 3nM, mTORC1 = 20nM, 
mTORC2 = 80nM 
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IC50, p110 = 7nM, p110 = 670nM  [34] 
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N
N
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IC50, p110 = 3nM, p110 = 170nM, p110 = 230nM 
 
[47] 
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IC50, p110 = 800nM, p110 >10μM 
 
[48] 
22 
H
N
O
N
S
N
O
N
H  
IC50 = 59nM, 1.006 μM, 18nM, 31nM for p110, p110, p110 
and p110 respectively 
[49] 
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24  N
N N
N
N
HN
NH2
 
IC50, p110, DNA-PK and mTOR of 52nM, 60nM and 10nM 
respectively; IC50 p110 and p110 = 1.4μM and 1.1μM 
respectively 
[51] 
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IC50, p110 = 11nM, mTOR = 17.5nM; GI50, LNCaP = 450nM, 
MDA468 = 1.7μM 
[52] 
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IC50, p110 = 29nM, p110 = 5.2μM [53] 
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N
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IC50, p110 = 3nM, p110 = 3.8nM  [53] 
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IC50, p110 = 3nM; 
>60-fold selectivity over p110; 
>200-fold specificity over p110, p110, DNA-PK and mTOR.  
[51] 
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Ki, p110 = 5nM   [55] 
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IC50, p110 = 14nM; IC50, p110 = 52nM  [56] 
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AS-605340: IC50, p110 = 8nM  [57] 
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N
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N
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N
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N
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IC50, p110 = 10nM  
IC50, p-AKT = 3.18μM  
[58] 
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IC50, p110 = 3nM  [61] 
 
are discussed below. Inhibitors of class IV PI3Ks involved in DNA 
repair are also of interest in cancer, but will not be covered here. 
3. ISOFORM-SELECTIVE PI3K INHIBITORS: HIS-
TORICAL LANDSCAPE AND RECENT PROGRESS 
Since the discovery of LY294002 1 [28] and the elucidation of 
the mechanism of action of the natural product Wortmannin 2 [29], 
both of which display activity against the class I PI3K isoforms, 
considerable progress has been made in the development of a 
plethora of structurally-diverse inhibitors that possess distinct 
subtype selectivity profiles. The properties of a number of these 
compounds – including some that have advanced into clinical 
development – have been reviewed extensively elsewhere [4, 30-
32]. Examples include the reversible, ATP-competitive p110/pan-
class I selective inhibitors GDC-0941, 3 [33,34], XL147, 4 [35], 
GSK1059615, 5 [36], and ZSTK474, 6 [37]; the irreversible p110 
inhibitor PX-866, 7 [29]; the p110-selective inhibitor CAL-101, 8 
[38]; the dual pan-class I/mTOR inhibitors SF1126, 9 [39], NVP-
BEZ235, 10 [40], XL765, 11 [41] and GSK1059615, 12 [36]; the 
dual p110/ inhibitor TG100115, 13 [29]; and the p110-selective 
TGX-221,  14 [42]. Clinical data for several of these agents are 
summarized in Section 5. Additional small molecule PI3K 
inhibitors reported to be in pre-clinical discovery or development as 
of mid-2009 include compounds 14 through 36 (Table 1), the 
biochemical, cellular and pharmacological properties of which have 
been chronicled previously [4], and which will not be discussed 
here. Rather, we illustrate the impact of structure-based drug design 
and focus on providing details of compounds disclosed in the 
primary and patent literature since that time. The chemical 
structures of these more recent compounds are listed in Table 2. 
 
3.1. Pan-Class I, Dual Pan-Class I/mTOR and Dual 
p110/mTOR Inhibitors 
3.1.1. Impact of Co-Crystal Structure Elucidation on the Design 
of Novel Small Molecule PI3K Inhibitors 
In considering the overall progress on the fascinating journey 
from early chemical tools to potent, selective and drug-like PI3K 
inhibitors that are now in the clinic, the exploitation of X-ray 
crystal structures of p110 catalytic domains to enable structure-
based design has been especially valuable [3]. As an example, Fig. 
(1) shows the co-crystal structure of the clinical pan-class I PI3K 
drug GDC-0941 3 bound to human p110. Overall there is a snug 
fit of the inhibitor in the ATP binding site and key features of the 
tridentate binding mode are: 1) the use of the morpholine oxygen to 
form a hydrogen bonding interaction with the amide of the hinge 
region Val 882 that is also bound by the adenine in ATP (left-hand 
side), representing an example of the privileged aryl morpholine 
structure that is seen commonly in many PI3K inhibitors; 2) the 
indazole moiety (right-hand side) which fits deep in the so-called 
affinity pocket and in which the two indazole nitrogen atoms form 
hydrogen bonds with the hydroxyl group of Tyr 867 and the 
carboxylate of Asp 841; and 3) the 4-methanesulfonyl–piperazin-1-
ylmethyl group (projecting out of the plane, centre) that points to 
the solvent channel and has a solubilising function, but also makes 
additional binding interactions with the protein through the 
piperazine ring lying close to the side chain of Met 804 and the 
sulfonyl group forming hydrogen bonds with Ala 805 and Lys 802 
at the mouth of the ATP pocket. Furthermore, the thienopyrimidine 
core is sandwiched between Met 953 and Ile 963 (forming the floor 
of the ATP pocket) and the side chains of Met 804, Trp 812 and Ile 
831 (which form the ceiling of the ATP site) [3,33, 34].  
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Structural biology insights are now facilitating both the design 
of new PI3K inhibitors with distinct isoform selectivities, and the 
interpretation of the binding properties of existing small molecules 
inhibitors of the superfamily. As an example of the impact of 
crystal structures and the potential for structure-based design, most 
PI3K inhibitors bind to p110 in a flat orientation, in the same plane 
as that adopted by the adenine of ATP; in contrast, an inducible and 
conformationally flexible specificity pocket is involved in the 
selectivity of compounds that act preferentially on p110, involving 
amino acid residues that are distal to the ATP binding site and that 
are more variable between p110 isoforms [106,107]. The  p110 
isoform is more conformationally flexible than p110 and p110, 
and inhibitors preferring p110 adopt a propeller shape which 
allows them to induce and access the specificity pocket. The 
specificity pocket appears to be more easily inducible and 
accessible in p110 compared to p110 and, moreover, it is 
predicted that p110 will be unable to undergo this conformational 
rearrangement. 
3.1.2. Recent Examples of New ATP-Competitive PI3K Inhibitors 
As mentioned above, we have previously chronicled details of 
the in vitro and in vivo properties of a plethora of diverse small 
molecule PI3K inhibitors developed up to mid-2009 (Table 1, 
compounds 14-36) [4]. A number of those compounds are now in 
clinical development, and are discussed in further detail below. 
Over the past 18 months, the field has continued to develop at a 
substantial pace, with many examples of novel ATP-competitive 
inhibitors having been disclosed in the literature during that time. 
There has, in particular, been significant progress made in the 
development of pan-class I/mTOR dual inhibitors, and of class I 
inhibitors with distinct isoform selectivity profiles. The dominant 
therapeutic focus continues to be cancer, although inhibitors of 
other isoforms – particularly p110 and p110 – with utility in the 
treatment of immune-inflammatory diseases – have also been 
developed. One significant development in the PI3K arena is the 
emerging, compelling evidence that targeting of p110 with Progress in the Preclinical Discovery  Current Medicinal Chemistry,  2011 Vol. 18, No. 18      2703 
selective small molecule inhibitors may provide therapeutic benefit 
in the treatment of autoimmune diseases [19], as well as in the 
treatment of specific (PTEN-null) tumour types [12]. This is a 
relatively unexplored area, however, and p110 inhibitors are 
scarce. However, we expect the discovery and development of such 
inhibitors to be the subject of increasing focus over the coming 
years. 
Table  2 lists the chemical structures of compounds 37-87, 
which represent a new series of small molecule PI3K inhibitors that 
have been reported in the literature during the last 18 months. These 
are predominantly reversible, ATP-competitive inhibitors, and 
many feature the aryl-morpholine structural unit, an established 
hinge-targeted structural motif. It is clear in these examples, 
however, that subtle structural modifications can lead to quite 
dramatic changes to class I and IV subtype selectivity. 
Yuan and co-workers have developed a series of potent 
demethoxyviridin derivatives which display significantly improved 
in vivo stability compared with demethoxyviridin. It was observed 
that esterification of the C1 position of demethoxyviridin led to an 
increase in serum half-life to two hours from 26 minutes; 
furthermore, conjugate addition with glycine furnished a derivative, 
37, whose half-life was 218 minutes, and which displayed an IC50 
of 44nM [62]. 
Researchers at the University of Auckland have disclosed 
results from their virtual screening approaches to the discovery of 
new chemical entities targeting PI3K activity [63]. Following in 
silico screening of the ZINC compound database, which comprises 
2.5 million compounds, a total of 89 new chemotypes were 
identified; biochemical screening subsequently led to the discovery 
of seven new compounds displaying activity between 1 and 100μM 
of which 38 was the most active, displaying pan-PI3K inhibition 
with an IC50 of 0.9μM, 3μM, 0.9μM and 4μM against p110, ,  
and  respectively. 
Gilbert and colleagues at Wyeth have reported the discovery of 
two structurally-related series based on purine[3,4-d]pyrimidines 
and pyrazolo[3,4-d]pyrimidines, exemplified by 39 and 40 
respectively [64]. Interestingly, subtle structural changes were seen 
to lead to dramatic alterations in subtype selectivity: compound 39 
had an IC50 of 58nM against p110, and displayed good selectivity 
over p110 and mTOR, whereas 40  showed more dual 
p110/mTOR activity (IC50  = 32nM and 83nM respectively), 
though with high selectivity over p110 (IC50 = 2367nM). 
Venkatesan and co-workers at Wyeth have outlined the 
development of imidazolopyrimidine derivatives exhibiting 
selective inhibition of both the class I isoforms and mTOR [65]. An 
example of such a compound is 41, which had an IC50 of 16nM and 
265nM against p110 and p110 respectively, but was inactive 
against mTOR. In a separate report, the same team also described 
the design, synthesis, and characterization of the highly potent 
bismorpholino-1,3,5-triazine derivative 42 (PKI-587), a potent dual 
class I PI3K/mTOR inhibitor [66]. This compound was seen to 
inhibit cell survival and proliferation, and to increase apoptosis in 
vitro and in vivo. PKI-587 also exerted potent anti-tumour efficacy 
in preclinical subcutaneous and orthotopic tumour xenograft 
models, and has now entered phase I clinical trials. A further report 
from Venkatesan et al. outlined the development of a related series 
of 1,3,5-triazine derivatives, targeted with the aim of improving the 
physicochemical properties of PKI-587 [67]. Incorporation of a 3-
oxa-8-azabicyclo[3.2.1]octane group in place of a morpholine 
resulted in the design of PKI-179, 43, which displayed potent in 
vitro activity (IC50 = 8nM, 74nM, 0.42nM against p110, p110 
and mTOR respectively). PKI-179 also has high oral 
bioavailability, and anti-tumour efficacy in the MDA-361 human 
breast tumour xenograft model. The compound was subsequently 
advanced into a phase I solid tumour study, though this trial has 
now been terminated. In a subsequent disclosure, it was revealed 
that, in in vitro studies, a major metabolite of PKI-179, 44, was 
generated following incubation in human liver microsomes [68]; 
Chen and co-workers confirmed that this metabolite displayed 
comparable in vitro potency to that of PKI-179.  
Dehnhardt et al. at Wyeth have described the discovery of a 
series of triazolopyrimidines, which led to the development of PKI-
402, 45, a dual p110/mTOR inhibitor (respective IC50s = 1.4nM 
and 1.7nM). PKI-402 displayed high anti-proliferative activity in 
tumour cell lines, induced apoptosis in vitro, and conferred potent 
anti-tumour efficacy in several tumour xenograft models [69]. In a 
further report, Zhang and co-workers at Wyeth outlined the 
discovery of a novel class of 5-ureidobenzofuran-3-one indoles also 
displaying potent p110/mTOR activity, exemplified by 46, which 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). X-ray co-crystal structure of the pan-class I selective PI3K inhibitor GDC-0941 (3) (PDB Code 3dbs). For more details see text and references [3, 33, 
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displayed very high biochemical activity (IC50 = 0.2nM and 0.3nM 
against p110 and mTOR respectively) with concomitant in vitro 
tumour cell growth inhibition (GI50 for inhibition of the growth of 
PC3 prostate cancer cells = 10nM). Compound 46 also displayed 
potent anti-tumour efficacy in the MDS-361 breast tumour 
xenograft model following daily iv dosing [70]. 
A report from Venkatesan et al. outlined the synthesis and 
characterization of 7H-pyrrolo[2,3-H]quinazolines with PI3K and 
mTOR activity [71]. The compound with the highest reported 
mTOR activity was 47 (IC50 = 2nM), though the structrually-related 
48 displayed potent p110 and p110 activity (respective IC50 
values of 22nM and 142nM). Compound 48 also conferred potent 
in vitro tumour growth inhibition (GI50 = 48nM, 70nM and 160nM 
against LNCap, MDA468 and hSMG1 cancer cells respectively). 
A series of 4-morpholinopyrrolopyrimidine derivatives was 
reported by Chen et al. to display both p110 and dual 
p110/mTOR activity. Compound 49 was found to be a selective 
and potent p110 inhibitor, with an IC50 of 21nM, whilst 50 had an 
IC50 of 0.9nM and 0.6nM respectively against p110 and mTOR 
[72].
Chen and colleagues have disclosed the discovery of a series of 
2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholines with activity 
against class I PI3Ks and mTOR. Compound 51  showed potent 
inhibition of p110 and p110, with respective IC50 values of 
0.9nM and 14nM. The tertiary amide derivative, 52, was reported to 
display highly potent biochemical inhibition of mTOR inhibition 
(IC50 of 300pM) [73]. 
Montagne et al. at Merck-Serono have reported the synthesis of 
a library of compounds based upon 2-morpholino-pyrido[3,2-
d]pyrimidines which exhibit PI3K activity. One example, 53, was 
reported to have an IC50 of 8nM [74]. In another report, Cardin and 
colleagues at Millennium disclosed the production of another 
targeted library, based upon a thiophene core, with PI3K activities 
in the 100nM-5μM IC50 range being obtained, including for 
compound 54 [75]. An additional library of thiophene derivatives 
designed by researchers at Millennium, with similar biochemical 
potencies, was reported by Renou et al., exemplified by 55 [76]. 
Bo  et al. at Amgen have disclosed the development of tri-
substituted pyridine derivatives displaying dual PI3K/mTOR 
activity [77], a key example of which was 56. This compound was 
reported to have an IC50 of 1.3nM and 0.6nM against p110 and 
mTOR respectively, and displayed high anti-proliferative potency 
in U87 glioma tumour cells (IC50 = 5.3nM). In a further report from 
Amgen, a series of di-substituted benzimidazole analogues were 
disclosed by Boezio and colleagues, displaying potent biochemical 
mTOR activity [78]. It was observed that specific substitution 
patterns governed selectivity for class I PI3Ks and mTOR; 
compound  57  displayed dual mTOR/p110 inhibition (IC50 = 
0.27nM and 0.65nM respectively), and potent growth inhibition 
activity in PTEN negative U87 cells (IC50 = 5nM). 
A new class of imidazo[1,2-a]pyridine derivatives with anti-
tumour activity has been disclosed by Bo et al. at Amgen [79]. 
Compound  58  displayed potent biochemical activity against 
p110 (Ki = 1nM) and mTOR (IC50 = 15nM), and potently 
inhibited U87 glioma tumour cell proliferation (IC50 = 7nM). 
Rewcastle et al. have disclosed a series of morpholino-triazines 
with specificity for p110, and which exhibit potent in vitro anti-
tumour efficacy [80]. A key example is compound 59, which was 
seen to be selective over p110 and p110 (0.1 < IC50 < 1 M), and 
inhibited NZOV9 cell proliferation with an IC50 < 0.1 M [80]. 
Heffron et al. have disclosed the characterization of GNE-477, 
60. This compound was seen to exhibit dual p110/mTOR 
inhibition (IC50 = 4 and 21nM, respectively), and displayed potent 
in vivo tumour growth inhibition in the PC3 prostate tumour 
xenograft model [81]. 
Cai and colleagues at Curis have reported the generation of a 
targeted array of small molecules based on the deazapurine, 
furopyrimidine and thienopyrimidine scaffolds that possess zinc-
binding moieties, and which display potent inhibition of p110, 
mTOR and histone deacetylase (HDAC) [82]. A representative 
example is 61, which showed potent inhibition of all three enzymes 
(IC50 < 100nM), and antiproliferative activities (GI50 < 100nM) in a 
tissue-diverse panel of tumour cells in vitro, including the   
HCT-116, BT-474, SK-MEL-28, and H1993 cancer lines. 
Baik and et al. at Exelixis have developed a series of 
pyridopyrimidinones with class I PI3K/mTOR activity [83]. A 
representative example, 62, was reported to display p110, 
p110 and mTOR inhibition with IC50 values of 5.5nM, 52.1nM and 
2.6nM respectively, and GI50  values of 15.8nM and 97.8nM 
respectively in PC3 prostate and MCF7 breast cancer cells. 
Cheng and colleagues at Pfizer have disclosed the development 
of PF-04691502, 63, a dual inhibitor of p110 (IC50 = 0.57nM) and 
mTOR (IC50 =16nM), with high in vivo efficacy in the p110 
mutant SKOV3 ovarian tumour xenograft model. PF-04691502 was 
subsequently advanced into a phase I, open label, dose escalation 
study in subjects with solid tumours [84]. 
Fairhurst and Imblach have reported the discovery of a series of 
4,5’-bisthiazoles with potent activity against the class I PI3Ks [85], 
notably p110. Representative compounds include 64 (IC50, 
p110, , ,  = 14nM, 6.51μM, 764nM and 1.28μM respectively) 
and 65 (IC50, p110, , ,  = 14nM, 4.94μM, 531nM and 531nM 
respectively). In a separate report, Caravetti et al. outlined the 
discovery of a related series of compounds again displaying 
selectivity for p110, including 66 (IC50, p110, , ,  = 14nM, 
4.43μM, 971nM and 680nM respectively), and 67, which also 
showed greater potency compared with 66  for p110 (IC50, 
p110, , ,  = 8nM, 1.21μM, 77nM and 1.09μM respectively) 
[86].  
Kim et al. have described the discovery of fluorescent xanthine-
based PI3K inhibitors with potent activity in T47D breast cancer 
cells. The principal biochemical activity of a representative 
compound disclosed in this report, 68, was p110 (IC50 = 150nM) 
[87]. 
Cheng and colleagues at Pfizer have reported the development 
of imidazo[1,5]naphthyridines with p110 and mTOR modulatory 
activity, and anti-tumour potency. One representative example is 
compound 69, which was amongst the most active dual-inhibitors 
disclosed (Ki, p110 = 167pM; mTOR = 232pM) [88]. 
Researchers at S*Bio have disclosed the discovery of a class of 
triazine-based inhibitors with p110/mTOR dual activity, 
exemplified by 70 (IC50 < 1μM) [89], and have, in a separate report, 
outlined the development of a series of purine derivatives with 
similar biochemical potencies, an example of which is 71 [90]. 
Morales  et al. at Semafore have developed a class of small 
molecule anti-tumour agents with class I PI3K and mTOR activity, 
exemplified by the 7H-thieno[3,2-b]pyran-7-one, 72 [91]. This 
compound exhibited dual class IA/mTOR activity (IC50, 
p110, , ,  = 297nM, 378nM, 784nM and 1.57μM respectively; 
IC50, mTOR = 610nM). 
Staben et al. have reported on the characterization of the p110 
inhibitors 73 and 74, which have respective IC50s of 162nM and 
6.8nM, and which display potent pharmacodynamic biomarker 
modulatory activity in vitro, notably effects on phosphorylation of 
AKT, PRAS40 and RPS6, in PC3 prostate cancer cells [92]. 
Finally, Large et al. have reported the in vitro biochemical and 
cellular activities of a series of trisubstituted pyrimidines, 
exemplified by 75 [93]. This compound displayed potent activity 
against p110 (IC50  = 62nM), and inhibited the proliferation of 
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compound also displayed potent down-regulation of phospho-AKT 
in the same cell line. 
3.2. Novel Inhibitors of p110, p110 and p110 
Fjellström et al. at AstraZeneca have demonstrated that (-)2-[1-
(7-methyl-2-(morpholin-4-yl)4-oxo-4H-pyrido [1,2-a]pyrimidin-9-
yl)ethylamino]benzoic acid, 76, displayed potent inhibition of 
p110 (IC50 = 21nM), with between 4- and 50-fold selectivity over 
the other PI3K isoforms [94]. In a separate report, Henteman and 
co-workers at Bayer have reported the discovery of sulfone 
substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives, 
exemplified by 77, with IC50 values against p110 of less than 
100nM [95].  
Ramsden and co-workers at Cellzome have outlined the 
production of a targeted array of 2-aminoimidazo[1,2-b]pyridazine 
analogues with PI3K activity, and with potential in the treatment or 
prophylaxis of immunological, inflammatory, autoimmune or 
allergic disorders [96]. The most active compound, 78, displayed 
high potency against p110 (IC50 < 0.2M) and 2-50 fold 
selectivity against the other PI3K isoforms. The same group has 
also outlined the discovery of 7-substituted aminotriazoles, 
exemplified by 79  [97], and urea triazolo[1,5-a]pyridine 
derivatives, exemplified by 80  [98], both of which display 
selectivity for p110 with IC50 values of less than 100nM. 
Ren and co-workers at Intellikine have reported the synthesis of 
a library based on a pyrazolopyrimidine core possessing a 
benzothiazole moiety. These compounds were seen to display 
activity against the class I PI3Ks and mTOR, with compound 81 
having an IC50 of less than 50nM against p110  and p110 and 
mTOR, through with selectivity over p110 [99]. In a separate 
report, the same group outlined the synthesis of a series of 
pyrazolopyrimidines which exhibited activity against one or all 
PI3K isoforms [100]. Compound 82 was reported to have an IC50 of 
100nM or less against p110 and p110 whilst having at least 100-
fold selectivity against the other two class I isoforms. 
Swinnen and co-workers at Merck-Serono have, in two separate 
reports, outlined the synthesis of libraries of small molecules based 
upon a [6,5]-heteroaromatic bicyclic core, with selective activity 
against p110, exemplified by 83 [101] and 84 [102]. In a further 
disclosure, Pomel and colleagues at Merck-Serono reported the 
production of a library based on 4-morpholino-pyrido[3,2-
d]pyrimidines, which also displayed preferential activity for p110; 
one example, 85, was reported to have an IC50 of 220nM [103].  
Researchers at Vertex have reported the development of a series 
of small molecule heterocycles, exemplified by 86, which target 
p110 [104], and which displayed in vivo disease arrest in 
preclinical models of experimential autoimmune encephalomyclitis 
(EAE). 
Finally, Bruce et al. at Novartis have disclosed the development 
of a new class of small molecules with p110 activity for use in the 
treatment of inflammatory and allergic diseases, an example of 
which is 87 (IC50 = 12nM) [105]. 
4. TRANSLATION TO THE CLINIC: MOLECULAR 
BIOMARKERS 
The small molecule inhibitors of the PI3K enzymes described 
in this review are expected to impact several disease areas, 
particularly oncology. Key to the translation of targeted 
therapeutics into the clinic, including PI3K inhibitors described 
here, is the identification and application of a number of types of 
biomarker [3]. These range from proof-of-mechanism markers, that 
can be used to ascertain whether the targeted agent has inhibited the 
activity of the target and cognate pathway, to prognostic or 
predictive markers that can be employed to select (or at least 
enrich) patient populations that are most likely to respond or to 
determine response to treatment.  
Proof-of-mechanism biomarkers are particularly useful in early 
clinical studies to confirm target and pathway modulation and to 
define the pharmacodynamic relationship to dose, toxicity and 
potential response in the Pharmacological Audit Trail [108]. 
Biomarkers that have prognostic value, an ability to estimate a 
given patient’s outcome regardless of the nature of treatment, or 
predictive value, an ability to estimate the efficacy or the toxicity of 
an individual patient to a given treatment, allow clinicians to deliver 
the most appropriate drugs to selected patients and to spare patients 
unnecessary treatment where they would not benefit from it. It is 
important to note that nearly half of all new oncology drugs 
approved by the FDA since the launch of trastuzamab have some 
form of patient selection biomarker incorporated [109]. These 
biomarkers primarily focus on target biomarkers in tumours that 
predict patient response, although, more recently, tumour 
biomarkers of resistance have also been employed, as with mutant 
KRAS in EGFR-directed therapies. However, although we have 
made great progress in understanding the complex genetic 
alterations that underlie human cancer, and there are now several 
leading examples of molecularly targeted drugs that have 
exemplified using companion molecular diagnostic assays for 
patient stratification, it has often proven difficult to identify 
precisely which molecularly-targeted therapeutics would benefit 
which particular patients [108].  
Significant progress has been made in identifying the most 
responsive tumour types and the underlying cellular pathways and 
molecular features determining response to PI3K inhibitors, in 
addition to pharmacodynamic biomarkers. However, it is clear that 
the situation is not simple, and that the choice of predictive 
biomarkers may well depend on the biology and genetics of the 
tumour type as well as the isoform selectivity profile of the agent 
concerned. To date several biomarkers potentially predicting 
tumour sensitivity have been investigated in preclinical and clinical 
settings, but none has yet been found to have a clearly defined, 
clinically qualified role for use in patients and thus more research is 
required. On the other hand, the emerging data show considerable 
promise and enrichment biomarkers are already in use in early trials 
of PI3K inhibitors in cancer patients.  
4.1. Biomarkers of Mechanism of Action in the Discovery and 
Development of PI3K Inhibitors 
Despite the scientific and technical challenges of identifying a 
biomarker which specifically and robustly gives a measure of PI3K 
pathway inhibition, excellent progress has been made and a number 
of biomarkers are now being used for preclinical and clinical work. 
The PI3K pathway is a protein kinase cascade activated following 
the production of PIP3 in the plasma membrane, and this pathway 
has many nodes and branches, such that there are numerous 
phospho-proteins that could be potential biomarkers of PI3K 
inhibition. Quantification of a biomarker close to the point of PI3K 
inhibition would be the ideal option as this would be the most likely 
to provide a direct measure or PI3K inhibition. PIP3, the product of 
the reaction catalyzed by PI3K, would ideally fulfill this 
requirement for a biomarker of pathway activity. However, while 
measuring PIP3 using mass spectroscopy, thin layer 
chromatography or ELISA-based methods with PIP3 detector 
proteins is feasible in vitro, the challenges of measuring PIP3 (both 
stability and methodology) in samples from patients are generally 
thought to be very considerable  at present. An alternative 
biomarker to PIP3 could be phosphorylation of a PDK1 substrate, 
since PDK1 is activated following recruitment to the plasma 
membrane by production of PIP3. AKT is directly phosphorylated 
at AKT
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of PI3K activity in in vitro tissue culture and in vivo tumour 
xenograft experiments [34]. However, the stability of 
phosphorylation of the AKT
THR308 site is generally thought not to be 
sufficiently robust for use in clinical studies. Other direct protein 
substrate targets of PDK1, such as SGKs, are yet to be explored as 
biomarkers of PI3K pathway inhibition. There has been 
considerable focus on phosphorylation of AKT
SER473 and some 
downstream proteins as preclinical and clinical biomarkers of PI3K 
activity. The downstream markers of activity include 
PRAS40
THR246, a substrate of AKT, and RPS6
SER240/244  and 
4EBP1
THR37/46. However, none of these biomarkers are perfect as 
they are not entirely specific for PI3K activation/inhibition because 
their phosphorylation can be influenced directly or indirectly by 
mTOR kinase activity. In addition, they may be influenced by 
inputs from other pathways, for example RPS6 can be 
phosphorylated by p90
S6K, a protein kinase regulated by other 
signalling cascades including MEK/ERK. Nevertheless they can 
play a useful research role. 
A number of studies have used unbiased screening strategies 
with the aim of identifying better and more specific biomarkers of 
PI3K inhibition for use in the development of PI3K inhibitors. 
Andersen and colleagues have employed immunoaffinity 
precipitation followed by mass spectrometry of protein extracts 
from cells that were treated with inhibitors of PDK1, AKT or 
PI3K/mTOR [110]. The aim of this study was to find specific 
biomarkers of PI3K pathway inhibition; it successfully led to the 
identification and quantification of 375 nonredundant 
phosphopeptides that were relevant to PI3K pathway signalling, and 
which contained AKT and PDK1 recognition motifs. Of these, 
seventy-one phosphopeptides were drug-modulated and 11 were 
reduced by all three inhibitors examined. An example was 
phosphorylation of the ribosomal protein RPS6 that was the most 
strongly inhibited by all 3 inhibitors and phosphorylation of 
PRAS40
THR246 which was the most affected following AKT and 
PI3K/mTOR inhibition. PRAS
THR246 was validated in lung and 
breast cancer cell lines and predicted sensitivity to an AKT 
inhibitor. Importantly, the phospho-PRAS
THR246 epitope was more 
stable than the phospho-AKT
SER473 epitope commonly used for 
identifying tumours with AKT pathway activation, suggesting that 
this biomarker might be more suitable for clinical evaluation of 
PI3K pathway inhibition. In particular it may be ideal for use in 
immunohistochemistry, which is often applied in clinical studies.  
The value  of using ELISA-based methodology to measure 
quantitatively the phosphorylation of pathway proteins that are both 
proximal and distal to PI3K has been demonstrated with several 
inhibitors including GDC-0941, with potency declining at more 
distal points (34). Interestingly, although inhibition of substrate 
phosphorylation was valuable as a measure of PI3K target 
inhibition, the degree of inhibition measured by immune-assay did 
not predict sensitivity in this study. 
An alternative non-biased approach for pharmacodynamic 
biomarker discovery is to use microarray expression profiling to 
identify gene signatures specifically associated with PI3K 
inhibition. Guillard and colleagues profiled gene expression 
following treatment of human glioma cells with the class I 
PI3K/mTOR inhibitor PI-103 (18) and detected  altered expression 
of genes encoding regulators of the cell cycle and cholesterol 
metabolism, together with genes modulated by insulin or IGF1 
signalling, rapamycin treatment or nutrient starvation [111]. 
Expression profiling of ex vivo treated peripheral blood 
mononuclear cells (PBMCs) has also detected a gene signature 
associated with inhibition of PI3K inhibition; this was validated in 
microarray expression profiling of mice treated in vivo [112]. 
Further validation of selected cell surface proteins identified from 
the gene signature determined that the altered expression was 
specifically induced by PI3K inhibition and not induced by selected 
cytotoxic agents, MEK inhibitors or the mTORC1 inhibitor 
rapamycin in vitro or in vivo. 
Some of the biomarkers described herein have been reported as 
having been examined in early clinical studies of PI3K inhibitors. 
While it is preferable to look at the effects of PI3K inhibitors on 
pathway activation in tumours, and this has been done, it is 
sometimes difficult to access the tumour, or to obtain repeat 
biopsies. Therefore assessment of PI3K signalling in alternative 
surrogate normal tissues has also been considered. One option is the 
hair follicle, which is convenient for repeat sampling and 
importantly has high PI3K pathway basal activity. For example, in 
mouse studies the PI3K inhibitor PX-866 decreased 
phosphorylation AKT
SER473 in both hair follicles and skin; also 
NVP-BEZ235 (10) has been reported to decrease RPS6
SER240/244 and 
AKT
SER473 phosphorylation in mouse skin [113,114]. Significantly, 
early clinical studies of XL765 have reported activity against 
phosphorylation of PRAS40
THR246, 4EBP1
THR37/46, RPS6
SER240/244 
and AKT
SER473 in patient hair follicles [115], while another study 
has reported decreased RPS6
SER240/244 in skin samples from patients 
treated with BMK120 [116]. PBMCs and platelet–rich plasma have 
also been considered as alternate tissues to determine PI3K pathway 
inhibition. Measurement of AKT
SER473 phosphorylation in PBMC 
lysates has proved too variable to be useful; however, analysis of 
AKT
SER473 levels in platelet-rich plasma has proved to be a 
successful alternative, and decreased AKT
SER473 has been reported 
following treatment of patients with GDC-0941 and GDC-0980 
[117-120]. Importantly, the extent of decreased AKT
SER473 
phosphorylation in platelet-rich plasma correlated with the dose of 
GDC-0941 and was concomitant with decreased RPS6
SER240/244 
phosphorylation
 in tumour biopsies. 
Demonstration of inhibition of PI3K signalling, generally using 
AKT
SER473 or RPS6
SER240/244 phosphorylation, has also been made in 
biopsies from solid tumours treated with XL147, GDC-0941, PX-
866 and XL765 while a study with the p110 specific inhibitor 
CAL-101 reported decreased AKT
THR308 in isolated lymphocytes 
from CLL patients [117-119,121-127]. 
In summarizing this section, various pharmacodynamic and 
proof-of-mechanism biomarkers have been developed which can be 
utilised to measure inhibition of the PI3K pathway in tumour 
biopsies and surrogate normal tissues. Use of these in early clinical 
trials is providing confidence that the pathway is inhibited by a 
given drug, and allows optimization of the dose and administration 
schedule (3). This forms an important part of the Pharmacological 
Audit Trail that is now important and widely used in the 
development of molecularly targeted drugs [108].  
4.2. Selecting Patients Likely to Respond to PI3K Inhibitors 
As PI3K inhibitors progress through the early clinical safety 
studies and into trials focusing on clinical efficacy, selection of the 
patient population most likely to benefit from treatment becomes an 
important consideration [108].  A better understanding of drug 
sensitivity and resistance mechanisms is critical to the successful 
development and application of targeted cancer agents [128].  A 
good example is the inherent resistance of tumours to anti-EGFR 
antibody and small molecule therapies resulting from the presence 
of a KRAS mutation and the sensitivity of patients to the gefitinib 
and erlotinib EGFR inhibitors in non-small cell lung cancer patients 
with activating EGFR mutations. We have previously emphasised 
the importance of identifying predictive biomarkers to select 
patients that will be responsive or resistant to PI3K or PI3K/mTOR 
inhibitors [3]. An overview and update is provided here.  
Boyd and colleagues have used reverse phase protein arrays, to 
profile the phosphorylation status of 100 proteins in a panel of 30 
breast cancer cell lines [129]. They found that sensitivity to the 
PI3K/mTOR inhibitor PI-103 was significantly correlated with 
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pathway, including AKT
THR308, AKT
SER473, PRAS
THR246 and 
FKHR
T24, suggesting that high levels of signalling through the 
pathway may be indicative of pathway addiction and be predictive 
of response to a targeted PI3K inhibitor. A study by Dan and 
colleagues came to a similar conclusion in a screen of a panel of 39 
cell lines, in which they observed that cancer cell lines with high 
AKT
SER473 were more sensitive to a range of PI3K inhibitors from 
different chemotypes [130].  However, there was no correlation 
observed between the level of AKT phosphorylation and PIK3CA 
mutation status [130,131]. In a separate study, there was no 
correlation seen between extent of pathway inhibition and 
sensitivity to PI3K inhibitors such as PI-103 and GDC-0941 [34]. 
A number of studies with different PI3K inhibitors have 
demonstrated that tumours with activating PIK3CA mutations or 
loss of PTEN expression are responsive to PI3K inhibition in vitro 
and  in vivo [34]. Serra and colleagues demonstrated that NVP-
BEZ235 had activity in tumours with PI3K activating mutations 
[114]. Two studies with the early prototype non-specific PI3K 
inhibitor LY294002 showed that cancer cell lines with PI3K 
mutations or, conversely, loss of PTEN  expression showed 
increased sensitivity to PI3K inhibition [10,132]. More recent 
studies with NVP-BEZ235 or GDC-0941 have also shown that 
tumours with activating PIK3CA mutations exhibit increased 
sensitivity to PI3K inhibition [34,133,134]. These observations 
would suggest that a patient group with activating PIK3CA 
mutations or loss of PTEN expression would be the most suitable 
for treatment with PI3K inhibitors. However, the predictive value is 
not completely clear as, within these studies, there are tumours 
without PIK3CA mutations or loss of PTEN expression  that are 
also sensitive to PI3K inhibition. Moreover, there are a number of 
in vitro or in vivo studies of cancer cell line panels that have failed 
to demonstrate the simple association of PIK3CA mutation or loss 
of PTEN expression  with sensitivity to PI3K inhibitors 
[129,130,135-137]. Therefore, at the moment, an informed but 
pragmatic approach to targeting a patient population with PIK3CA 
mutations or PTEN expression loss with PI3K inhibitors is 
generally being used – one in which PIK3CA mutation and loss of 
PTEN expression is employed to enrich for patients that will tend to 
be more likely to respond to PI3K pathway inhibition. At the same 
time, we must also keep an open mind as it is clear that some 
tumours without these genetic abnormalities can be equally 
sensitive to PI3K inhibition, and recognize that the identification 
and validation of additional predictive biomarkers or signatures will 
be necessary. This research is ongoing. 
A confounding factor in determining the influence of activating 
mutations of the PI3K pathway on response to PI3K inhibitors may 
be the presence of other activated oncogenes. Mutations of KRAS 
are frequently co-incident with PIK3CA mutations 
(http://www.sanger.ac.uk/genetics/CGP/Census/). This may be 
related to the observation that KRAS and PIK3CA interact and, in 
mouse tumourigenesis models, PIK3CA has been shown to be 
required for KRAS-driven tumourigenesis through direct interaction 
[138]. Similarly, Engleman and colleagues have demonstrated in a 
mouse model of lung cancer that PI3K signalling is required for 
KRAS-driven tumourigenesis [139]. In that study, the mouse 
tumours driven by the PIK3CA
H1047 mutation were responsive to 
NVP-BEZ235, but not rapamycin. In contrast, tumours driven by 
mutant KRAS were seen to be insensitive to NVP-BEZ235. In a 
similar vein, Ihle and colleagues noted that mutant PIK3CA and 
loss of PTEN activity were sufficient, but not necessary, as 
predictors of sensitivity to the anti-tumour activity of the PI3K 
inhibitor PX-866 in vivo in the presence of wild-type RAS, whereas 
mutant oncogenic RAS was a dominant determinant of resistance, 
even in tumours with coexisting mutations of PIK3CA [135]. In 
support of this, a study of a number of PI3K inhibitors from 
different chemotypes in a panel of 39 cancer cell lines in vitro and 
24  in vivo tumour  xenografts found a significant association of 
activating RAS or BRAF mutations with resistance to inhibition of 
the PI3K pathway [130]. Moreover, an additional study of 84 non-
small cell lung cancer cell lines demonstrated reduced sensitivity in 
those with activating RAS mutations [137]. 
Additional potential factors associated with increased 
sensitivity to PI3K inhibition have also been identified. Sos and 
colleagues have shown that the presence of mutated or amplified 
receptor tyrosine kinase in non-small cell lung cancer cell lines 
correlated with increased sensitivity and apoptosis following 
treatment with PI3K inhibitors [137]. On the other hand, in the 
study of Faber and colleagues, inhibition of PI3K/mTOR signalling 
in non-small cell lung cancers with activating mutations of EGFR 
did not induce apoptosis,  in contrast to HER2-amplified breast 
tumours in which sensitivity was seen [140]. Several further studies 
in breast cancer cells have also shown that the presence of 
amplified  HER2 or the dual presence of PIK3CA mutation  and 
HER2  amplification increases sensitivity to NVP-BEZ235 and 
GDC-0941, potentially through an increased cell death response 
[133,134].  In contrast to the HER2-amplified breast tumours, 
inhibition of PI3K/mTOR signalling non-small cell lung cancers 
with activating mutations of EGFR did not induce apoptosis. 
Importantly, even if an initial response to targeted therapies is 
successfully obtained, it is likely that the majority of tumours will 
at some later point acquire resistance to therapy, and become 
refractory to treatment [128].  This can either be a result of the 
acquisition of additional mutations or alternatively arise from the 
outgrowth of a resistant sub-clone already present in the tumour cell 
population. In the clinic this has been exemplified by tumours that 
acquire mutations of BCR-ABL, KIT, PDGFR and EGFR during 
treatment, where the mutated proteins are no longer susceptible to 
inhibition by the targeted agent, but retain enzymatic activity and 
the ability to promote cell growth and survival [141,142]. As PI3K 
inhibitors progress through the clinic it is possible that acquired 
resistance may also become a factor. Zunder and colleagues have 
addressed this issue using a S. cerevisiae screen against a 
structurally diverse panel of PI3K inhibitors [143]. They identified 
a potential hotspot for resistance mutations (PIK3CA
I800) and a 
drug-sensitizing mutation (PIK3CA
L814C). Resistance to small 
molecule inhibitors of protein kinases can occur as a result of 
mutations at one particular position in the active site. This mutated 
residue is known as the gatekeeper because it controls access to a 
large hydrophobic pocket in which most protein kinase inhibitors 
bind, and mutations of this type have now been reported for a 
number of protein kinases. In the case of EGFR, the gatekeeper 
mutated proteins retain receptor tyrosine kinase activity, but do not 
bind the EGFR inhibitor [141]. Importantly, the screen of Zunder et 
al. did not reveal resistance mutations at the gatekeeper residue and, 
in fact, these were unlikely to occur with PI3K inhibitors as 
introduction of gatekeeper mutations into PIK3CA resulted in a loss 
of enzymatic activity. Thus, the induction of resistance to PI3K 
inhibitors by this mechanism may be less likely than is the case for 
many protein kinase inhibitors. 
In summary, predictive biomarkers are now emerging that will 
help us to select patients that are more sensitive to PI3K inhibition. 
It is already clear that sensitivity and resistance is multifactorial and 
that the biomarkers already identified, including phosphorylation of 
PI3K pathway substrates, PIK3CA mutation, wild type KRAS and 
BRAF, loss of PTEN expression, HER2/ERBB2 amplification, and 
gene expression signatures, should be seen as useful enrichment 
biomarkers rather than  truly predictive biomarkers at this time 
[3,108]. There are likely to be confounding molecular factors 
affecting sensitivity and resistance in cancer cells and in addition 
the effects of PI3K inhibitors on processes such as angiogenesis and 
the tumour microenvironment are also likely to be important and 
contribute to therapeutic activity. The particular tumour type 
context and the particular isoform selectivity profile of the 
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needed to fully define, scientifically and technically validate, and 
clinically qualify the predictive biomarkers needed for eventual 
patient stratification in the event that PI3K inhibitors receive 
regulatory approval. 
5. CLINICAL TRIALS IN CANCER 
A number of class I and dual class I/mTOR inhibitors have now 
entered clinical trial [144]. In this section we provide an update on 
the current status. 
5.1. Pan-Class I Selective PI3K Inhibitors 
Pan-class I selective PI3K inhibitors have been shown to be 
well-tolerated and, in general, to induce minimal and reversible 
effects on serum glucose despite the established role of p110 in 
regulating insulin signalling. Other effects with ATP-competitive 
PI3K inhibitors include skin toxicity (rash and urticaria). 
Encouragingly, tumour responses stable disease and other signs of 
clinical efficacy have been reported in many clinical studies and in 
a variety of human cancers. 
Data on the clinical safety of the peptidic prodrug of 
LY204002, SF1126, in patients with advanced or metastatic 
tumours have been reported [145,146]. These studies demonstrated 
good tolerability and activity of the drug administered iv, which led 
to disease stabilization in patients with refractory tumours, 
including renal cell carcinoma and chronic lymphocytic leukaemia 
(CLL). Toxicities that were reported include nausea, vomiting, 
fatigue, urticaria and rash. No glucose or insulin changes have been 
reported. Evidence of pathway modulation has been claimed. Dose 
limiting toxicity has been reported at 1100mg/m
2. 
XL147 was assessed in an open label, phase I dose escalation 
study that was carried out in patients with advanced solid tumours 
and lymphoma. Using a standard 3+3 design, patients with solid 
tumours received once daily XL147 on days 1-21 (21/7) or as a 
continuous daily dose in 28-day cycles. [121,122]. The 3+3 trial 
design is used for the majority of oncology phase I trials. According 
to this design, which is simple and straightforward to use, patients 
are treated in cohorts of 3; then, depending on the number of dose-
limiting toxicities seen in the particular patient cohort, decisions are 
made on which dose to give the next cohort or whether to stop the 
trial. The maximum tolerated dose was 600 mg in both schedules. 
The most common drug-related toxicity that was seen was skin 
rash. Inhibition of PI3K and ERK pathway signalling was 
demonstrated in solid tumours, and prolonged stable disease has 
been observed in patients with cancers including non-Hodgkin’s 
lymphoma and non-small cell lung cancer. Two phase 1 
combination studies have been reported with XL147. The 
combination with the EGFR inhibitor erlotinib was generally well 
tolerated at doses up to 400 mg XL147/150 mg erlotinib with no 
major pharmacokinetic interaction and resulted in clinical activity 
and robust simultaneous inhibition of PI3K and EGFR signalling 
[147,148].  The second combination study with paclitaxel and 
carboplatin showed that XL147 is well tolerated at doses up to 600 
mg in combination with 175 mg/m
2 and AUC 6 of paclitaxel and 
carboplatin respectively with no major pharmacokinetic interaction 
or emerging toxicities. Robust pharmacodynamic activity and 
tumour regression in heavily pre-treated patients have been 
observed in this study. Expansion cohorts will include patients with 
endometrial, ovarian and non-small cell lung cancer.  
Phase I clinical trials are currently being conducted with GDC-
0941 [117,118]. Initial results have been reported from a phase I 
study using a 3+3 escalation design with a single dose of GDC-
0941 and a 1-week washout, followed by GDC-0941 QD 
administered on a 3-week on, 1-week off schedule. A dose-
proportional increase in drug exposure was observed from 15 to 
450mg. Target modulation was reported with inhibition of 
AKT
SER473 phosphorylation in platelet-rich plasma at doses above 
80mg and a decrease in RPS6 immunostaining in tumours. In 
addition, objective decreases in metabolic activity as measured by 
positron emission tomography of fluorodeoxyglucose (
I8FDG-PET) 
have been observed in patients’ tumours at doses above 80mg. 
GDC-0941 was generally well tolerated and exhibited signs of anti-
tumour activity in a variety of cancers including breast, ovarian 
cancer, gastro-intestinal stromal tumour (GIST) and melanoma 
patients. Toxicities include fatigue, nausea, diarrhea and rash. 
Transient hyperglyceamia has been described. GDC-0941 is being 
evaluated in non-small cell lung cancer in combination with 
paclitaxel and carboplatin with or without bevacizumab. So far, 
these combinations appear to be well tolerated and no sign of 
pharmacokinetic interaction have been observed. Dose escalation is 
ongoing and clinical activity has been recorded [119]. A phase II 
study in breast cancer is recruiting  
In an initial phase  1 dose-escalation study evaluating an 
intermittent dosing schedule, PX-866 was well tolerated with 
diarrhoea and nausea observed as main toxicities. PX-866 was 
rapidly converted to an active metabolite (17-OH PX-866) which 
demonstrated improved potency relative to parent compound in 
kinase and cellular assays [123]. PX-866 was further evaluated 
using a continuous dosing schedule and has been well tolerated at 
8mg per day and associated with better disease control in heavily 
pre-treated patients than intermittent dosing. Clinical responses 
have been observed in pancreatic islet cell, colorectal, and prostate 
cancer. Predictive biomarkers are being explored.  
Patients were treated at 6 doses of BMK30 ranging from 12.5 
mg to 150 mg [116]. The maximum tolerated dose was 100 mg. 
Treatment-related adverse events included rash, hyperglycaemia, 
diarrhoea, nausea, anorexia, pruritus, fatigue, mood alteration, 
malaise, vomiting, and mucositis. Preliminary pharmacokinetic 
analysis showed rapid absorption and low clearance from plasma 
leading to steady-state drug exposure estimated to be potentially 
efficacious based on preclinical data. Downregulation of pS6 in 
skin was seen in all patients at 100/150 mg. At 100 mg, 8 of 10 
evaluable patients showed metabolic partial response by FDG-PET. 
Clinical responses were observed in triple negative breast cancer, 
colorectal cancer, angiosarcoma and lung cancer. 
5.2. Dual Pan-Class I PI3K/mTOR Inhibitors 
The safety profile and tolerability of the dual pan-PI3K/mTOR 
inhibitors generally appears to be similar to that of the pan-
inhibitors. Several organizations are developing candidates with 
both profiles and it is currently unclear what the ideal PI3K family 
isoform selectivity profile or profiles in the clinic will be. Signs of 
clinical activity are also encouraging for the development of these 
agents. 
The first reports from clinical trials conducted in patients with 
solid tumours showed promising drug safety and tolerability for 
NVP-BEZ235 with signs of clinical activity in patients with 
tumours bearing PI3K pathway alterations [149].  Toxicities that 
were reported included nausea, vomiting, diarrhea, fatigue/asthenia, 
anemia, and anorexia; these effects were mild or moderate, 
manageable, and reversible upon treatment discontinuation. AUC 
and Cmax were found to increase non-proportionally with dose and 
were variable within and among patients. NVP-BEZ235 exhibited 
dose- and day-dependent PI3K inhibition as measured by elevation 
of plasma C-peptide levels. 2 partial responses (1 Cowden 
syndrome patient, 1 breast cancer patient) and 16 measurable 
responses were observed. 14 of 51 evaluable patients had stable 
disease for 4 months; tumours from 6 of these 14 patients carried 
dysregulation of the PI3K pathway. Four of the 14 (29%) patients 
with stable disease for 4 months had breast cancer. 18 of 35 
evaluable patients had detectable decreases of 
18FDG uptake. An 
improved formulation of the compound will be used in future 
studies.  Progress in the Preclinical Discovery  Current Medicinal Chemistry,  2011 Vol. 18, No. 18      2709 
XL765 was administered twice daily (BID) or daily (QD) for 
28-day cycles with a standard 3+3 dose escalation design in patients 
with solid tumours and lymphoma. The most common related 
adverse events (> 10% of patients) were observed to be nausea, 
diarrhoea, anorexia, elevated liver enzymes, skin disorders, and 
vomiting. Exposure was found to be increased with increasing 
doses on BID and QD schedules. Robust pharmacodynamic 
modulation of PI3K and ERK pathway signalling was evident both 
in tumours and surrogate tissues following dosing of XL765. For 
example, decreases in phosphorylation of AKT
THR308 (57-76%) or 
of 4EBP1 (62-80%), as well as ERK (53-80%), were observed in 
paired biopsies of various solid tumours from patients receiving 50 
mg BID. Eleven patients have been reported to be on study for  16 
weeks and seven patients on treatment for  24 weeks.  The 
maximum tolerated dose for single-agent XL765 is reported as 50 
mg BID. XL765 exhibited potent pharmacodynamic activity in 
solid tumours and surrogate tissues at generally well tolerated doses 
[126]. XL765 in combination with the DNA methylating agent 
temozolomide is well tolerated at doses up to 40 mg QD. There 
was no apparent pharmacokinetic interaction between XL765 and 
temozolamide. Maximum tolerated dose determinations for QD and 
BID schedules are ongoing. Signs of disease stabilisation have been 
observed. XL765 in combination with erlotinib is also generally 
well tolerated at daily doses up to 50 mg XL765/100 mg erlotinib 
with no apparent pharmacokinetic interaction, and results in robust 
inhibition of PI3K and EGFR signalling in skin and tumour tissue. 
The maximum tolerated dose for the combination has not yet been 
determined [124,125]. 
The phase I dose escalation study of GDC-0980 was carried out 
in patients with solid tumours or non-Hodgkin's lymphoma and 
used a 3+3 design [120]. GDC-0980 was given on day 1, followed 
by 1week washout to investigate single-dose pharmacokinetic and 
pharmacodynamic biomarkers. The most frequently reported 
adverse events were nausea (25%), fatigue (50%), diarrhoea (42%), 
and flatulence (25%). GDC-0980 was found to be generally well 
tolerated up to 16 mg administered orally QD with potential signs 
of anti-tumour activity. Preliminary pharmacokinetic data suggest 
dose-proportional increases in Cmax and AUC. Initial 
pharmacodynamic biomarker data showed >50% inhibition of 
phosphorylated AKT
SER473 levels assayed in platelet-rich plasma 
after a single dose of 8 mg and higher of GDC-0980. Of potential 
interest, evidence of anti-tumour activity was observed in a 
mesothelioma patient previously treated with radiation and 
cisplatin. The recommended dose is yet to be established  
Two candidates from Pfizer are currently being developed, one 
for i.v. administration (PF-04691502), and one for oral dosing PF-
05212384  [150,151]. Both compounds are dual PI3K/mTOR 
inhibitors and show acceptable pharmacokinetic profiles after 3 
dose escalations. So far no clinical activity has been reported. 
Pharmacodynamic biomarker assessment is being performed by 
measurement of glucose and insulin levels in blood. Nausea, 
fatigue, headache and hyperglycaemia have been the most 
frequently reported treatment-related adverse events so far. Dose 
escalation is ongoing for both compounds  
5.3. p110-Selective PI3K Inhibitors 
The potent p110-specific inhibitor CAL-101 exhibits 40- to 
300-fold selectivity for that particular isoform, as compared to other 
PI3K enzymes and is undergoing Phase I clinical evaluation in 
relapsed or refractory haematological malignancies (CLL, acute 
myeloid leukaemia, multiple myeloma and non-Hodgkin’s 
lymphoma) [127]. The first interim reports from phase I trials with 
CAL-101 show promising drug activity and a lack of severe 
toxicity in haematological cancer patients. Plasma exposure was 
shown to increase with dose. AKT
THR308 as a marker of PI3K 
activation was measured in cells from a subset of chronic 
lymphocytic leukaemia patients with circulating lymphocytes and 
was observed to be reduced by >90% following dosing, 
demonstrating target inhibition.  
6. SUMMARY AND FUTURE PERSPECTIVE 
As mentioned earlier in this review, the progression of PI3K 
inhibitors over the last twenty years or so has been remarkable. 
There are a number of interesting and important features that can be 
highlighted. 
First is the evolution from chemical tool compounds, like 
LY294002 1, Wortmannin 2 and PI-103 18 [152], to drugs that are 
now beginning to show pharmacodynamic evidence of target 
modulation and clear signs of therapeutic benefit to cancer patients 
[3,153]. 
Next to highlight is the impact of the crystal structures of p110 
catalytic domains, facilitating the interpretation of isoform 
selectivity profiles and the prospective design of desired profiles 
[3,154-156]. In the landmark study by Knight et al. [106], common 
selectivity combinations were identified, as with agents that exhibit 
preferences for p110/p110 and p110/ (termed ‘pharmalogs’). 
Inhibitors of p110 often also inhibit the class IV isoforms DNA-
PK and mTOR, as with PI-103, but it has been possible to remove 
the class IV inhibition from class I-selective inhibitors as in case of 
GDC-0941  3 compared to PI-103 [34]. The desirability of 
p110/pan-class I isoform selectivity for cancer therapy is still 
being debated [3,34,107].  It is now clear that highly selective 
inhibitors of p110 can be produced and that p110/ inhibitors can 
also be obtained, for potential use in inflammation. Many variations 
on these core patterns exist. Although mouse models will help, it is 
likely that the preferred isoform selectivity profiles for medical use, 
as distinct from chemical tools, will only emerge following detailed 
clinical evaluation of multiple agents. For future drug design, the 
SAR rules for achieving selectivity are progressively being defined, 
facilitated by the increasing availability of crystal structures. In 
addition to the various isoform-targeted inhibitors developed to 
date, there is also significant emerging potential for p110 and dual 
p110/ inhibitors for the treatment of immune-inflammatory 
diseases and cancer [19, 12, 157-160] and also of p110 inhibitors 
in the latter therapeutic area [161]. 
Also important has been the use of proof of mechanism 
pharmacodynamic biomarkers to demonstrate target and pathway 
modulation in both the preclinical discovery phase and the early 
clinical development of PI3K inhibitors. This is critical in the 
implementation of the Pharmacological Audit Trail [108], enabling 
rational optimization of dose and schedule of administration as well 
as go/no go decision-making. In addition, progress has also been 
made on the identification of potential predictive biomarkers for the 
identification of patients that are most likely to respond to PI3K 
inhibitors. These include PIK3CA mutation, PTEN expression loss, 
HER2/ERBB2  amplification/overexpression, wild type KRAS and 
gene expression signatures. 
Finally to be highlighted is the emerging picture from the clinic 
of PI3K inhibitors as generally well tolerated agents that are already 
beginning to show evidence of single agent therapeutic activity in 
early clinical trials in cancer patients. Concerns about potential 
effects on glucose metabolism appear to have been alleviated, with 
only mild effects being seen, at least with the doses and schedules 
used to date. 
What then are the key issues facing the preclinical discovery 
and clinical development of class I PI3K and class I/class IV 
inhibitors for cancer treatment? 
Identifying optimal isoform selectivity profiles has already been 
discussed and is ongoing. Related to this point, more work needs to 
be done to identify the best predictive markers of sensitivity for 
drugs with different selectivity profiles. In addition, further research 
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essential. At the moment the available biomarkers are probably best 
described as enrichment biomarkers – for use in enriching early 
clinical trials for patients with malignancies with molecular 
characteristics (PI3K pathway addiction) that make them more 
likely to respond. Much more work needs to be done to validate and 
clinically qualify biomarkers that may be truly predictive. It needs 
to be remembered that, especially since PI3K inhibitors can have 
effects on tumour angiogenesis and tumour microenvironmental 
interactions, there may not be a single biomarker of sensitivity but 
rather a group of these or a predictive molecular signature. Studies 
in preclinical systems, including large molecularly characterised 
cancer cell panels and human tumour xenografts, together with 
genetically engineered mouse models, will be useful for this. 
However, it is likely that many of the answers will be worked out 
by molecular profiling, including cancer genome sequencing, of 
clinical tumour material and the correlation of such data with 
therapeutic response and outcome. 
Many PI3K inhibitors are now progressing through phase II 
single agent efficacy studies and the results are eagerly awaited by 
the oncology community. Combination studies are also underway. 
Because of the number of potential combinations, it may take some 
time to identify optimal combinations and both preclinical and 
clinical studies will be important for this. Some rationally based 
combinations, for example with MEK inhibitors, have obvious 
mechanistic appeal and these are being prioritized [3]. 
In addition to cancer indications, there is exciting potential for 
PI3K inhibitors in other therapeutic contexts, particularly immune 
inflammation and cardiovascular disease.  
It has been a fascinating journey so far with PI3K inhibitors. 
With the range of agents now coming through that have distinct and 
attractive profiles, in the next few months and years there should 
increasing opportunities to reveal further evidence of clinical utility.  
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